



<b>Study Title:</b>	Treatment Trial for Older Individuals with Newly Diagnosed AML
<b>Scientific Title:</b>	ECOG E2906: Phase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia
<b>Department and/or Specialty:</b>	RCC-Heme-AML
<b>Investigator:</b>	Michael Thompson, MD, PhD
<b>Contact Information:</b>	Chanda Miller 262-928-5539
<p>Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination therapy) may kill more cancer cells. It is not yet know which chemotherapy regimen is more effective in treating acure myeloid leukemia.</p> <p>This randomized phase III trial is studying clofarabine to see how well it works compared with danuoribcin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia.</p>	



**PROHEALTH CARE**  
RESEARCH INSTITUTE